

Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

Listing of Claims

1-126. (Canceled).

127. (Currently amended) A method of treating ~~or preventing~~ an affective disorder which comprises administering to a patient ~~in need of such treatment or prevention~~ a therapeutically ~~or prophylactically~~ effective amount of a bupropion metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, wherein the bupropion metabolite, or pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, is adjunctively administered with a therapeutically ~~or prophylactically~~ effective amount of a second pharmacologically active compound for the treatment ~~or prevention~~ of said affective disorder.

128. (Previously presented) The method of claim 127, wherein the bupropion metabolite is optically pure (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.

129. (Previously presented) The method of claim 127, wherein the affective disorder is alcohol addiction, an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity, attention deficit/hyperactivity disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, cocaine addiction, depression, narcolepsy, nicotine addiction, obesity, premenstrual syndrome, seasonal affective disorder, or weight-gain.

130. (Previously presented) The method of claim 128, wherein the affective disorder is alcohol addiction, an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity, attention deficit/hyperactivity disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, cocaine addiction,

depression, narcolepsy, nicotine addiction, obesity, premenstrual syndrome, seasonal affective disorder, or weight-gain.

131. (Previously presented) The method of claim 127, wherein the second pharmacologically active compound is a selective serotonin reuptake inhibitor, a 5-HT₃ inhibitor, or nicotine.

132. (Previously presented) The method of claim 128, wherein the second pharmacologically active compound is a selective serotonin reuptake inhibitor, a 5-HT₃ inhibitor, or nicotine.